Caplin Point Labs Recommends ₹3/Share Dividend, Q1 Net Profit Up 20.7%

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Caplin Point Laboratories' board has recommended a final dividend of ₹3 per equity share (150%) for the financial year ended March 31, 2025. The dividend, if approved at the forthcoming Annual General Meeting (AGM), will be paid on or before October 21, 2025. The board also reported a 20.7% year-on-year increase in consolidated net profit to ₹150.76 crore for the quarter ended June 30, 2025 (Q1 FY26), with revenue from operations increasing by 11.2% to ₹510.22 crore.

The total dividend for the financial year 2024-25, including the final dividend (subject to shareholder approval), will be ₹6 per equity share (300%) of the face value of ₹2 each. An interim dividend of ₹3 per equity share (150%) for FY25 was declared on May 15, 2025, and paid to shareholders on June 9, 2025.

Financial Performance

• Consolidated revenue for Q1 FY26 stood at ₹533.36 crore, an 11.7% increase compared to ₹477.52 crore in Q1 FY25.
• EBITDA for Q1 FY26 was ₹200.90 crore, up 17.9% from ₹170.37 crore in Q1 FY25.
• The company's net profit margin for Q1 FY26 was 28.3%, compared to 26.2% in Q1 FY25.

Segmental Performance:

• Revenue from Rest of the World segment was ₹403.53 crore in Q1 FY26, compared to ₹381.06 crore in Q1 FY25.
• USA revenue increased to ₹106.69 crore in Q1 FY26, up from ₹77.90 crore in Q1 FY25.

Other Highlights:

• Gross Margin for Q1 FY26 is 61.7% vs 59.6% in Q1 FY25, supported by new product launches.
• EBITDA Margin for Q1 FY26 is at 37.7% vs 35.7% in Q1 FY25.
• Basic EPS increased by 23.1% to ₹20.10 in Q1 FY26 compared to ₹16.32 in Q1 FY25.
• Cash Flow from Operations in Q1 FY26 is ₹118 Crores vs ₹96 Crores in Q1 FY25.
• Free Cash Flow is ₹53 Crores (after Capex investment of ₹65 Crores) in Q1 FY26 as compared to ₹59 Crores (after capex investment of ₹37 Crores) in Q1 FY25.

The company is actively seeking out acquisition of land/plants in the US. Initial plans are to warehouse our own products before moving to Packaging and eventually Manufacturing, if commercial viability is established.

CSU has launched 24 products till date, with a further 15+ products to be launched in FY26.

The Board approved convening the 34th Annual General Meeting of the Company on 22nd September, 2025 through Video Conferencing / Other Audio-Visual means.

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates.